• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals (NQ: ALNY )

    264.31 -17.18 (-6.10%)
    Streaming Delayed Price Updated: 1:08 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alnylam Pharmaceuticals

    < Previous 1 2
    ...
    9 10 11 12 13 14 15 16 Next >
    Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Expert Ratings for Alnylam Pharmaceuticals
    Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
    Via Benzinga
    Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine
    Via Benzinga
    Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
    The company isn't seeking an injunction, but wants "fair compensation." 
    Via Investor's Business Daily
    Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
    The company isn't seeking an injunction, but wants "fair compensation." 
    Via Investor's Business Daily
    Analyst Ratings for Alnylam Pharmaceuticals
    Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
    Via Benzinga
    Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease
    Via Benzinga
    Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
    Upgrades 
    Via Benzinga
    5 Best And Worst Performing Large-Cap Stocks In June 2022
    Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022. 
    Via Talk Markets
    Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
    The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
    Via Benzinga
    Where Alnylam Pharmaceuticals Stands With Analysts
    Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
    Upgrades 
    Via Benzinga
    The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate
    The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary... 
    Via Benzinga
    Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
    Upgrades 
    Via Benzinga
    Alnylam to Webcast Presentations at Upcoming June Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam to Webcast Presentations at Upcoming May Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    10 Biggest Price Target Changes For Monday
    Morgan Stanley boosted Archer-Daniels-Midland Company (NYSE: ADM) price target from $69 to $94. Archer-Daniels-Midland shares fell 0.5% to $89.10 in pre-market trading. 
    Via Benzinga
    Expert Ratings for Alnylam Pharmaceuticals
    Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
    Via Benzinga
    The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals
    Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
    Via Benzinga
    The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
    Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
    Via Benzinga
    < Previous 1 2
    ...
    9 10 11 12 13 14 15 16 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.